One-year evaluation of recombinant human tumor necrosis factor-alpha receptor II decrement combined with thalidomide increment in the treatment of active ankylosing spondylitis

Zhou Jin; Fu Lin; Zhou Zhen; Li Qiurong

doi:10.3969/j.issn.2095-4344.1955

Home>Articles>One-year evaluation of recombinant human tumor necrosis factor-alpha receptor II decrement combined with thalidomide increment in the treatment of active ankylosing spondylitis

DOI: 10.3969/j.issn.2095-4344.1955

One-year evaluation of recombinant human tumor necrosis factor-alpha receptor II decrement combined with thalidomide increment in the treatment of active ankylosing spondylitis

Zhou Jin

Fu Lin

Zhou Zhen

Li Qiurong

Machine-generated Keywords：

Publication Date：2019-01-01

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：6( 5664-5669 )

Chinese Journal of Tissue Engineering Research

PKUISTIC

ISSN：2095-4344

Year, Vol.(Issue)：2019,23(35)